Scarica l'app Stockscreener
4.11
11.08%
0.41
Dopo l'orario di chiusura:
4.06
-0.05
-1.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.70
Aprire:
$3.7
Volume 24 ore:
23.06M
Relative Volume:
1.35
Capitalizzazione di mercato:
$1.84B
Reddito:
$263.44M
Utile/perdita netta:
$-390.98M
Rapporto P/E:
-3.6664
EPS:
-1.121
Flusso di cassa netto:
$-336.24M
1 W Prestazione:
+19.13%
1M Prestazione:
+16.43%
6M Prestazione:
+83.48%
1 anno Prestazione:
+134.86%
Intervallo 1D:
$3.69
$4.20
Intervallo di 1 settimana:
$3.28
$4.20
Portata 52W:
$1.66
$5.63
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
4.11 | 1.65B | 263.44M | -390.98M | -336.24M | -1.121 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Aggiornamento | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
IOVA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Assessing Iovance Biotherapeutics (IOVA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
IOVA Stock Slides As Guidance Tops Wall Street Expectations - StocksToTrade
IOVA Stock Slides After Q1 Miss As Amtagvi Growth Accelerates - timothysykes.com
Can Iovance (IOVA) Turn Early Amtagvi Data and Manufacturing Tweaks into a Durable Advantage? - Sahm
Iovance Biotherapeutics to Present at Upcoming Conference - The Manila Times
IOVA Technical Analysis | Trend, Signals & Chart Patterns | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Iovance Biotherapeutics’ SWOT analysis: stock gains momentum on melanoma data - Investing.com
IOVA Stock Price, Quote & Chart | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
symbol__ Stock Quote Price and Forecast - CNN
Iovance Biotherapeutics, Inc.Common Stock (NQ: IOVA - The Chronicle-Journal
Iovance’s Terminated TIL Study Reshapes Expectations for Solid-Tumor Growth - TipRanks
What Iovance Biotherapeutics (IOVA)'s Amtagvi Momentum and Narrowing Losses Means For Shareholders - Sahm
Barclays Maintains Iovance Biotherapeutics (IOVA) Overweight Recommendation - MSN
Earnings call transcript: Iovance Biotherapeutics Q1 2026 misses EPS, revenue forecasts - Investing.com UK
IOVANCE (NASDAQ: IOVA) CCO reports RSU vesting and tax share withholding - Stock Titan
Iovance slips after Q1 miss amid in-line 2026 outlook - MSN
Iovance (IOVA): The Best Penny Stock to Buy Before It Explodes - Insider Monkey
Iovance Biotherapeutics | SCHEDULE 13G: Others - Moomoo
State Street (NASDAQ: IOVA) holds 17.45M shares, 4.2% stake - Stock Titan
Chardan Cuts Iovance (IOVA) Price Target, Keeps Buy Rating - Insider Monkey
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate) - Seeking Alpha
10 Best US Stocks Under $5 to Buy - Insider Monkey
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11 - Moomoo
IOVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionIOVA - TMX Newsfile
Iovance Biotherapeutics (IOVA) Trailing Loss Improvement Tests Bearish Profitability Narratives - Sahm
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2026 Earnings Call Transcript - Insider Monkey
Why Iovance Biotherapeutics (IOVA) Is Up 5.7% After AMTAGVI-Driven Q1 Revenue Jump And Share Plan - Yahoo Finance
Is Iovance Biotherapeutics’ (IOVA) Stock Authorization Request Quietly Rewriting Its Financing Playbook? - Sahm
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13% - TradingView
Iovance Therapeutics: Q1 Earnings Miss May Have Created A Buying Opportunity (NASDAQ:IOVA) - Seeking Alpha
A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $14 - Moomoo
Iovance Biotherapeutics Q1 Earnings Call Highlights - Barchart.com
Iovance Biotherapeutics Price Target Cut to $14.00/Share From $16.00 by Chardan Capital - Moomoo
TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Iovance Biotherapeutics Shares Drop After Q1 Results Miss - Moomoo
Earnings call transcript: Iovance Biotherapeutics Q1 2026 misses EPS forecast By Investing.com - Investing.com South Africa
IOVA Stock Holds Key Range As Biotech Traders Watch Support - StocksToTrade
Evaluating Iovance Biotherapeutics (IOVA) Valuation After A Sharp Short Term Share Price Rebound - Sahm
Iovance Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Earnings call transcript: Iovance Biotherapeutics Q1 2026 misses EPS forecast - Investing.com
IOVANCE BIOTHERAPEUTICS, INC. 1Q 2026: Revenue $71.43M, EPS $(0.19) — 10-Q Summary - TradingView
Strong Q1 growth at Iovance (NASDAQ: IOVA) with 2026 revenue guidance - Stock Titan
IOVA Stock Grinds Higher As Traders Track Biotech Turnaround - timothysykes.com
Iovance Biotherapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):